Below are short case reports of our clinical experience using GcMAF immunotherapy in our clinics at Saisei Mirai. Most patients are on a variety of both conventional and complementary therapies, and most commonly they have come to us after conventional therapies have failed. Since our therapies are non-toxic they can be used successfully at any stage to improve quality of life (QOL), prolong life and cure the disease.
Common therapies at our clinic include:
Symptoms: Insomnia, bladder infections needing to void 10 times per night, Optic neuritis (inflammation of the optic nerve), severe muscle pain and twitching, confusion, weakness, wheelchair bound, unable to walk or stand. Multitude of bacterial infections.
Responded very well from the start to GcMAF. Slept through the night to 7 AM to use his bladder. He has gone off all medications for pain and bladder control and is off antibiotics. He has more energy and is able to drive an adapted car. He is also going to work every day. He still doesn't walk and he still has some confusion.
Has full bladder control and off medication for bladder infections and also patches to assist bladder to function. Brain fog is much better and he is animated and happy.
Patient is continuing treatment with 2nd Generation GcMAF.
Patient information and summary of result:
Integrative Therapies: Iressa targeted therapy, 1500 ng High Dose GcMAF 2 times weekly IM injection for 6 months (48 times total), Regional Hyperthermia, 8 times (Thermotron RF8), 4.5 mg Low Dose Naltrexone (LDN) daily.
Primary doctor was surprised because the result expected from the targeted therapy was only stable disease (rather than curative) because of advanced stage, but the tumor completely disappeared with only some scar tissue remaining in the lungs.
Patient achieved complete response by August 2013.
Glioblastoma multiforme (GBM), is the most common and most aggressive malignant primary brain tumor in humans. Treatment can involve chemotherapy, radiation and surgery. Median survival with standard-of-care radiation and chemotherapy with temozolomide is 15 months. Median survival without treatment is 4.5 months. Less than 15 % people survive 2 years.
Patient, aged in his 70s, used tumor derived cancer vaccine and then continued with GcMAF long-term. Patient still alive and well after 2 years.
60 year old male with prostate cancer, Gleason score 8 diagnosed in February 2011. He received radical prostatectomy without hormonal therapy, but after the surgery his PSA was increasing again. He received radiation therapy, 60 Gray to his pelvic region. In May 2012, he presented at Saisei Mirai. He received 72 times 0.5 ml high-dose GcMAF (1500 ng/0.5 ml), high dose IV vitamin C 60g and 21 times regional hyperthermia using Thermotron RF8.
In February 2013, MRI showed no metastatic tumors. The latest PSA level in 2014 was 0.058 ng/ml with no recurrence.
Patient was diagnosed stage 4B after initial surgery in February 2011. Pathological diagnosis was Serous Adenocarcinoma.
Prior treatment was 2 times chemotherapy in March 2011 with Carboplatin and Paclitaxel. After 2 times chemotherapy Pet CT showed recurrence in the left iliac artery and lymph nodes, and tumor markers were elevated. Patient then had second surgery of lymph nodes metastasis in the pelvis and left inguinal region and in addition prophylactic surgery.
In July 2011 patient had more chemotherapy with CDDP and radiation therapy, but new recurrence was found in the lymph node near the abdominal aorta which was followed by a fourth operation in November 2011, and at the same time radiation therapy near the abdominal aorta.
Patient presented at Saisei Mirai Clinics in Osaka in December 2011 after extensive prior treatment. Chemotherapy had been discontinued due to weakening condition of patient from side effects.
Immunotherapy was started at our clinic from December 2011, initially with Regional Hyperthermia, 400 mg/day Maitake MD-fraction and Low Dose Naltrexone (LDN). Maitake MD-fraction and LDN were continued long-term. Coley Vaccine therapy (Coley Toxin's) was started in January 2012 and High Dose GcMAF (1500 ng, 0.5 ml) from February 2012.
Intravenous Coley Vaccine, total 110 times, starting at 5 times 1st week, then 2 times 2nd week, followed by 5 times 3rd week, and so on, finishing with 1 time per week at the end. High Dose GcMAF (total 48 times), once per week, over a period of 1 year.
By 2013 patient achieved complete remission. No tumor was visible in CT scan and tumor marker was at the bottom end of the normal range.
High Dose GcMAF (1500 ng, 0.5 ml) was administered once a week (total 48 times) together with weekly high-dose intravenous Vitamin C (total 56 times). One year later, the patient still has good quality of life (QOL) with stable disease and no change in the size of the tumor. Patient discontinued GcMAF because he felt the treatment had been successful, however 6 months later the CT showed tumor growth. After this result the patient decided to continue treatment with GcMAF. Currently patient's condition is stable with good QOL.
High Dose GcMAF (1500 ng, 0.5 ml) was administered once a week (total 24 times) together with weekly high-dose intravenous vitamin C (total 39 times). Local Hyperthermia (Thermotron RF8) was added once a week (total 19 times). The patient had complete response. Primary tumor and multiple bone metastases have all disappeared according to the bone scintigram (bone scan/bone scintigraphy) and MRI.
First the patient had surgery to remove the tumor in the colon and the ovary was also removed. Then she took High Dose GcMAF (1500 ng, 0.5 ml) treatment once a week (total 48 times) and high-dose intravenous vitamin C once or twice a week (total 66 times). During this period of time, she took targeted radiation therapy (Novalis Tx Radiosurgery) to the liver tumor at a dose of 55Gy. After one year's treatment, PET CT scan showed no recurrence of the tumor. She is still in complete remission.
Patient took conventional therapy with all available tuberculosis antibiotics for 10 years with good effect initially. After 10 years of treatment, tolerance to the drugs increased and therapy lost effectiveness. After this she decided to start high-dose intravenous vitamin C (25 g) once a week (total 239 times) over a 4 year period and she took High Dose GcMAF (1500 ng, 0.5 ml) once a week (total 41 times) for about 1 year near the end of the 4 year period. After 4 years of treatment her chest CT scan showed only scar tissue without active infiltrations in the lung.
Advanced stage lung cancer patient had low-dose palliative radiation to their right lung (left side on the scan) to treat cough and breathing difficulty caused by cancer. This radiation therapy was not designed to have significant effect on the cancer, but was simply to treat the symptoms. After one-time palliative radiation treatment and High Dose GcMAF (1500 ng, 0.5 ml) therapy, patient's right-side lung (viewed on the left in the photo), shrank by half and tumor marker also decreased by half from CEA 890 ng/ml to 426 ng/ml, 2 months later.
Radiologists treating the patient were amazed at the good effects, which were not common or expected with this kind of low-dose radiation treatment. Symptoms greatly improved with a significant decrease in cough and improved breathing, and patient remained active with good quality of life. We believe that the use of multimodality integrative therapy of GcMAF plus a low dose of radiation was enough to be effective, avoiding serious side effects of regular high-dose radiation. What is more surprising is that this occurred at the very advanced stage having completed all available therapies (such as chemotherapy) which is when treatments become less effective as the cancer becomes resistant and difficult to treat. When using GcMAF therapy, better results are seen with local treatments such as radiation (avoiding the bone marrow) over systemic conventional chemotherapies which harm the immune system.
If you wish to purchase GcMAF therapy or make an enquiry, please contact us with details of your disease, current treatment and the quantities of Gc-MAF you require.
Purchase your Colostrum MAF here using PayPal or credit card.Heart Pharmacy website
Thank you very much for your participation at the Saisei Mirai 2016 Integrative Medical Therapies conference in Osaka, held on Sunday 13th November 2016.2016 Integrative Medical Therapies conference - Osaka, Japan
Dr Toshio Inui
Dr. Toshio Inui gave a presentation of the electric field therapy and second-generation GcMAF and colostrum MAF at a conference which was held in Jakarta, Indonesia on July 22, 2016.
14 to 15-JUL-2016
Dr. Shinichiro Akiyama at International Pharmacy Conference, which was held in the United States Philadelphia, Pennsylvania on July 14 to 15, 2016, the Clinical experience of colostrum derived protein against solid cancer has been announced as the Keynote Speaker.
New research papers on Oral Colostrum GcMAF for Chronic Fatigue Syndrome (CFS) and serious infection published in Anticancer Research journal.Research paper
Clinical application of Second Generation GcMAF and oral GcMAF
Dr Toshio Inui
Indications for GcMAF for immunotherapy of cancers and chronic viral and bacterial infections (PDF)
Dr Toshio Inui
Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy (PDF), PPT
Dr Toshio Inui
New research papers on GcMAF and integrative cancer immunotherapy treatment written in collaboration with the University of Tokushima, Kanazawa University and Kobe University Graduate School of Medicine researchers and Saisei Mirai published in Anticancer Research journal.Research paper
The results show that 2nd Generation GcMAF is stable for 1 year at 4 °C, for 14 days at room temperature (around 20 °C), and for 7 days at 40 °C.
See Research and references for more details on experiments on macrophage phagocytic activity and stability of our GcMAF.
Boeki Center Building
5-1-14 Hamabetori Chuo-ku
Nature 21 Building
TEL: +81 (0)6-6902-1001
ORE Hiroo Building
ORE Hiroo Building
Nature 21 Building